CG
AXDX

Cutler Group’s Accelerate Diagnostics AXDX Stock Holding History

Cutler Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$9K – 3993
2019
Q4 		$9K Hold
500
– – ﹤0.01% 2684
2019
Q3 		$16K Buy
+500
New +$96.6K ﹤0.01% 2319
2018
Q1 		– Sell
-1,160
Closed -$16K – 4426
2017
Q4 		$16K Buy
1,160
+110
+10% +$25.8K ﹤0.01% 2738
2017
Q3 		$13K Sell
1,050
-180
-15% -$44.2K ﹤0.01% 3530
2017
Q2 		$45K Buy
1,230
+210
+21% +$56.9K ﹤0.01% 2588
2017
Q1 		$15K Buy
1,020
+420
+70% +$96K ﹤0.01% 3603
2016
Q4 		$13K Buy
600
+260
+76% +$61.7K ﹤0.01% 3888
2016
Q3 		$33K Buy
340
+110
+48% +$24.3K ﹤0.01% 2887
2016
Q2 		$4K Buy
+230
New +$30.8K ﹤0.01% 5073

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Cutler Group's AXDX Position: Q3 2021 in Review

Cutler Group sold out of Accelerate Diagnostics (AXDX) in Q3 2021, closing a stake of 240 shares — an estimated $19K sold.

Cutler Group first reported a position in AXDX in Q4 2015 and held it in 16 quarters. The position peaked at $835K in Q2 2017. 105 funds tracked by Wall St. Rank hold AXDX as of Q3 2021.

  • Cutler Group reported no remaining Accelerate Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Cutler Group sold 240 Accelerate Diagnostics shares in Q3 2021, an estimated $19K.
  • Cutler Group first reported a position in Accelerate Diagnostics in Q4 2015 and held it in 16 quarters.
  • Cutler Group's Accelerate Diagnostics position peaked at $835K in Q2 2017.
  • 105 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.